Aufrufe: 9
Nick Calvert, Chief Executive Officer, and Michael Gottlieb, Executive Board Chair, will present an overview of Yellowbird's platform and its lead program, NeuCaVis™, a novel metabolic PET imaging agent designed to enable precise visualization of inflammation. The Company recently announced dosing of the first participants in its Phase I clinical trial at the University of Ottawa Heart Institute.
In addition to the presentation, members of the Yellowbird management team will participate in one-on-one meetings with investors during the conference.
2026 Bloom Burton & Co. Healthcare Investor Conference
Presenters: Nick Calvert, Chief Executive Officer; Michael Gottlieb, Executive Board Chair
Date: Tuesday, April 21, 2026
Time: 10:30 a.m. ET
Location: Metro Toronto Convention Centre, Toronto, Canada
About Yellowbird Diagnostics
Yellowbird Diagnostics is an Ottawa-based biotechnology company developing next-generation metabolic imaging agents to detect disease earlier and guide clinical decision-making. The Company's lead program, NeuCaVis™, is a first-in-class PET tracer targeting fructose metabolism as a marker of inflammation, with potential applications across cardiovascular disease, neuroinflammation, and oncology. Yellowbird is advancing its platform through clinical development with the goal of improving diagnostic precision and enabling better patient outcomes.
For more information, visit www.yellowbirddx.com
Contacts
Michael Gottlieb, Yellowbird Diagnostics Inc.
michael@yellowbirddx.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292637
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
